An evaluation of ticagrelor for the treatment of sickle cell anemia.

An evaluation of ticagrelor for the treatment of sickle cell anemia. Expert Rev Hematol. 2020 Sep 24;:1-9 Authors: Ribeiro-Filho J, Yahouédéhou SCMA, Pitanga TN, Santana SS, Adorno EV, Barbosa CG, Ferreira JRD, Pina ETG, Dos Santos Neres JS, Leite IPR, Lyra IM, Goncalves MS Abstract INTRODUCTION: Ticagrelor is an antiplatelet agent approved for the treatment of patients with an acute coronary syndrome or a history of myocardial infarction. Considering the evidence demonstrating that ticagrelor-mediated inhibition of platelet activation and aggregation have beneficial effects in the treatment of thrombotic conditions, clinical studies have been conducted to evaluate the use of this drug for the treatment of sickle cell disease (SCD), demonstrating satisfactory tolerability and safety. AREAS COVERED: Clinical investigation has characterized the pharmacokinetic and pharmacodynamical profile, as well as the efficacy and safety of ticagrelor to prevent painful vaso-occlusive crisis (painful episodes and acute chest syndrome) in SCD patients. EXPERT OPINION: While phase 1 and 2 clinical trials demonstrated satisfactory tolerability and safety, the conclusion of phase 3 clinical trials is crucial to prove the efficacy of ticagrelor as a therapeutic option for the treatment of SCD. Thus, it is expected that ticagrelor, especially in combination with other drugs, will improve the clinical profile and quality of life of patients with SCD. ...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research

Related Links:

ConclusionsThe present analysis suggests that fondaparinux is safer than UFH in the management of OHCA due to AMI by reducing early bleeding complications at one month.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionsIn SR patients with CAD and HF, the rates of MI and stroke associated with rivaroxaban combined with APT were lower than those associated with APT alone, and the two treatments had similar rates of all-cause death and major bleeding.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionsThere were no demonstrable treatment differences across SGLT2 inhibitors across cardiovascular, renal, and metabolic outcomes, although this needs to be interpreted considering the wide confidence intervals, limited number of included studies, and heterogeneity present. Future research of different SGLT2 inhibitors in head-to-head studies is warranted to determine if there is a drug class effect.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
AbstractReproducibility of clinical output is important when investigating therapeutic efficacy in pre-clinical animal studies. Due to its physiological relevance, a swine myocardial infarction (MI) model has been widely used to evaluate the effectiveness of stem cells or tissue-engineered constructs for ischemic heart diseases. Several methods are used to induce MI in the swine model. However, it is difficult, using these approaches, to obtain a similar level of functional outcomes from a group of animals due to interpersonal variation, leading to increased experimental cost. Hence, in order to minimize human intervention...
Source: European Journal of Applied Physiology - Category: Physiology Source Type: research
This study is par for the course, looking at Japanese Olympic participants. Interestingly, it hints at the upper end of the dose-response curve for physical activity, in that a longer career as a professional athlete may be detrimental in comparison to lesser degrees of exercise and training. From this large, retrospective cohort study targeting 3546 Japanese Olympic athletes, we observed significant lower mortality among Olympians compared with the Japanese general population. The overall standardised mortality ratio (SMR) was 0.29. The results were consistent with previous studies conducted in other non-Asian co...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
A popular New Jersey high school principal died Sunday after donating bone marrow to a young boy in France, his family confirmed to news outlets. Derrick Nelson, who was the principal at New Jersey’s Westfield High School, never recovered after falling into a monthlong coma following a bone marrow donation procedure at a Bergen County hospital, his father told NJ.com. Nelson died Sunday at age 44, though the exact cause of his death was unclear, his father said; he told ABC News that his son may have had a heart attack. Nelson was donating bone marrow to supply stem cells to a 14-year-old boy in France with an undisc...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Education New Jersey onetime Source Type: news
In this study, we used HUT as the means to provide an all-encompassing assessment of cardiac and/or peripheral autonomic function in normal controls, SCD subjects and non-SCD subjects with chronic anemia. We hypothesized that by identifying different categories of HUT response among these subjects, we would be able to isolate the autonomic phenotypes that might place SCD subjects at increased risk for microvascular occlusion and VOC. We then employed the causal modeling approach, which utilizes signal analysis and system identification techniques, to probe and disentangle the functional mechanisms involved in the cardiovas...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Abstract Sickle cell disease (SCD) is one of the most common hereditary hemoglobinopathies worldwide, affecting almost 400,000 newborns globally each year. It is characterized by chronic hemolytic anemia and endothelial dysfunction, resulting in a constant state of disruption of the vascular system and leading to recurrent episodes of ischemia-reperfusion injury (I/RI) to multiple organ systems. I/RI is a fundamental vascular pathobiological paradigm and contributes to morbidity and mortality in a wide range of conditions, including myocardial infarction, stroke, acute kidney injury, and transplantation. I/RI is c...
Source: The American Journal of Pathology - Category: Pathology Authors: Tags: Am J Pathol Source Type: research
Sickle cell disease (SCD) is one of the most common hereditary hemoglobinopathies worldwide, affecting almost 400,000 newborns globally each year. It is characterized by chronic hemolytic anemia and endothelial dysfunction, resulting in a constant state of disruption of the vascular system and leading to recurrent episodes of ischemia-reperfusion injury (I/RI) to multiple organ systems. I/RI is a fundamental vascular pathobiological paradigm and contributes to morbidity and mortality in a wide range of conditions, including myocardial infarction, stroke, acute kidney injury, and transplantation.
Source: American Journal of Pathology - Category: Pathology Authors: Tags: Review Source Type: research
Sickle cell disease (SCD) affects millions worldwide. Sickle cell anemia (SCA), the most severe form of this disease, is the most common inherited blood disorder in the United States. There is limited data on the incidence, clinical characteristics and outcomes of acute myocardial infarction (AMI) in these patients. Using data from the National Inpatient Sample (NIS) database, we matched cases (AMI with SCA) with controls (AMI without SCA) in 1:1 ratio for age, gender, race and year of admission.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
More News: Anemia | Clinical Trials | Heart Attack | Hematology | Sickle Cell Anemia | Study